Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome

Journal of Surgical Research

Volumn 100, Issue 1, 2001, Pages 11-17

  Bold, Richard J ^a   Virudachalam, Subbulakshi ^a   McConkey, David J ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; GEMCITABINE; LUCIFERASE; PROTEASOME; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2;

ANIMAL MODEL; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG SENSITIZATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL;

EID: 0034875305     PISSN: 00224804     EISSN: None     Source Type: Journal    
DOI: 10.1006/jsre.2001.6194     Document Type: Article

References (32)

1. Cancer statistics 1996
2. Pancreatic cancer: The greatest oncological challenge
3. Cancer of the pancreas
4. The ubiquitin-proteasome proteolytic pathway
5. The ubiquitin-proteasome pathway in cancer
6. Programmed cell death and the proteasome
7. p27Kip1 accumulation by inhibition of proteasome function induces apoptosis in oral squamous cell carcinoma cells
8. Proteasome-dependent regulation of p21WAF1/CIP1 expression
9. Rel/NFκB/IκB family: Intimate tales of association and dissociation
10. Rel/NF-kappaB represses BCL-2 transcription in pro-B lymphocytes
11. A pathway of neuronal apoptosis induced by hypoxia/reoxygenation: Roles of nuclear factor-kappaB and BCL-2
12. Gemcitabine-induced apoptotic cell death of human pancreatic carcinoma is determined by BCL-2 content
13. BCL-2 and p53 expression in resectable pancreatic adenocarcinomas: Association with clinical outcome
14. Introduction of recombinant vectors into mammalian cells
15. Structure-function analysis of bcl-2 protein. Identification of conserved domains important for homodimerization with bcl-2 and heterodimerization with bax
16. Inhibition of NF-kappaB activation in vitro and in vivo: Role of 26S proteasome
17. Proteasome inhibitors: A novel class of potent and effective antitumor agents
18. Proteasome inhibition: A new strategy in cancer treatment
19. The proteasome inhibitor PS-341 in cancer therapy
20. Potent and selective inhibitors of the proteasome: Dipeptidyl boronic acids
21. Proteasome inhibition attenuates nitric oxide synthase expression, VCAM-1 transcription and the development of chronic colitis
22. Rapid colorimetric assay for cell growth and survival: Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability
23. Lactacystin, proteasome function, and cell fate
24. An essential role for NFκB in preventing TNFα-induced cell death
25. Suppression of TNFα-induced apoptosis by NFκB
26. A proteasome inhibitor prevents activation of NFκB and stabilizes a newly phosphorylated from of IκB-α that is still bound to NFκB
27. Ubiquitin, proteasomes, and the regulation of intracellular protein degradation
28. The nuclear factor-kappaB RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells
29. Construction of adenovirus for high level expression of small RNAs in mammalian cells. Application to a BCL-2 ribozyme
30. Antitumor effect of adenovirus-mediated BAX gene transfer on p53-sensitive and p 53 resistant cancer lines
31. Tumor suppressor p53 is a direct transcriptional activator of the human BAX gene
32. Increased sensitivity of CLL-derived lymphocytes to apoptotic death activation by the proteasome-specific inhibitor lactyacystin